BBIO BridgeBio Pharma Inc

$BBIO is going against $PFE and doing well $TGTX against Roche .:: and others For $VKTX is much easier as consumer driven.. news spread like 🔥 . If they offer something $50 cheaper then $LLY they could take 20% of Lilly business. They will be limited by supply and this is why BI cut deals with 4 sources. I can’t see Lilly just watching at the end. ..

$BBIO 2 headlines here today. Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records "In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p<0.01)" Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 "100% of participants who received encaleret reported improvements in at least one ADH1 symptom compared to 46% of participants who received standard of care today presented bone turnover results and patient-reported outcomes from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The data were presented in oral presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting in Boston, Massachusetts. Additionally, the Company dosed the first participant in RECLAIM-HP, its registrational Phase 3 study of encaleret in adults and adolescents with chronic hypoparathyroidism."

$BBIO 🏥 BridgeBio Pharma, Inc. reported Phase 3 CALIBRATE trial results showing encaleret increased bone turnover and improved ADH1 symptoms in 100% of participants versus 46% on standard of care, and the FDA accepted its NDA with Priority Review and a PDUFA date of May 8, 2027.

three dates stacked and nobody is talking about the first one $BBIO has BBP 418 PDUFA Nov 27, priority review, first therapy for limb girdle muscular dystrophy type 2I if it lands. FORTIFY hit every endpoint at the 12 month check then infigratinib Feb 4 and encaleret May 8. three dates on the calendar inside six months Attruby is already doing the heavy lifting, 253 million in Q3, and acoramidis data hits AHA this weekend. stock near 74.35, flat today, up about 5% on the week. 21 days out and the room is quiet

Attruby did the heavy lifting again imo $BBIO closed Friday at 74.95, up about 6% from 70.73, after Q3 revenue jumped to about 353 million from about 121 million a year ago Attruby itself pulled about 253 million, up from last quarter, and the quarter beat on both revenue and the loss per share Nov 27 is circled for BBP 418, so it's walking into Monday with momentum and a catalyst still ahead

40 days out and $BBIO still isn't getting talked about like a name with a clean Phase 3 win in hand Nov 27 PDUFA BBP 418 for LGMD2I R9 Priority Review FORTIFY met every primary and secondary endpoint at the 12 month interim, treated patients improving while placebo declined if approved it's the first therapy for any form of LGMD. ngl that part matters more than the usual label guessing

$BBIO Company had a one time milestone payment in the sales fig. Even so, they did increase sales again for attruby. There are a few hidden pros here. They will surely get 3 approvals in the coming months. Data is super strong. Also they will be eligible for id say 3 PRVs a value of about 600 MUSD. In addition they did exactly what i anticipated, they revise their hypochondroplasia study doses, increasing. This was very very fortunat timing and rational considering strong safety data AND the competing strong PH3 data from vosoritide. Actually necessary to beat them. And with higher doses i believe vosoritide will be beaten.

$BBIO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.42 up 55.79% YoY • Reported revenue of $353.17M up 192.60% YoY

$BBIO Im wondering if this thing is starting to wake up? Earnings report is tmr after close (Oct 29th) And perhaps more importantly: PDUFA for BBP-418 due by Nov 27. I am optimistic.

$BBIO someone completely faked the tape right before AH ended. What a joke. Thesis strengthening materially.

$BBIO reports earnings today after the close. I used Stock Meadow’s earnings dashboard to review its history: BBIO has beaten EPS estimates in 2 of its last 8 reports.

$BBIO Latest analyst update, Oct 21, 2026: Morgan Stanley kept Overweight and cut its price target on BridgeBio Pharma to 87 USD from 97 USD. Third-party analyst opinion. More details in our $BBIO stock hub. Not investment advice.